Tenax Therapeutics (TENX) EBITDA Margin (2011 - 2015)

Tenax Therapeutics (TENX) posted quarterly EBITDA Margin of 9874.97% for Q2 2015, down 1346.87% on a QoQ basis from 682.51% in Q2 2013.

Tenax Therapeutics (TENX) EBITDA Margin (2011 - 2015) Analysis & Trends

Tenax Therapeutics has reported EBITDA Margin for 5 years, with the latest figure at 9874.97% in Q2 2015.

EBITDA Margin for Q2 2015 came in at 9874.97%, changed N/A year-over-year; the trailing twelve-month figure through Jun 2016 was 29548.27% (down 2868261.0% YoY), and the FY2015 annual result was 33603.73%, changed N/A from the prior year.
EBITDA Margin slipped to 9874.97% in Q2 2015, from 682.51% in the prior quarter.
Over five years, EBITDA Margin peaked at 10360.51% in Q1 2011 and troughed at 9874.97% in Q2 2015.
A 4-year average of 967.77% and a median of 715.64% in 2013 frame the typical range for EBITDA Margin.
The largest YoY upside for EBITDA Margin was 914614 bps in 2012 against a maximum downside of 1162433 bps in 2012.
A 4-year view of EBITDA Margin shows it stood at 2158.73% in 2011, then jumped by 94 bps to 132.62% in 2012, then tumbled by 415 bps to 682.51% in 2013, then sank by 1347 bps to 9874.97% in 2015.
Per Business Quant data, the three most recent EBITDA Margin figures were 9874.97% in Q2 2015, 682.51% in Q2 2013, and 715.64% in Q1 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	138.75 Bn	130.90 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	85.96 Bn	77.96 Bn	3.93 Bn	30.15%
3	Argenx Se	64.98 Bn	59.80 Bn	1.37 Bn	32.54%
4	Moderna	56.33 Bn	51.19 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	42.03 Bn	36.93 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	31.56 Bn	28.25 Bn	992.69 Mn	17.93%
7	BioNTech SE	27.74 Bn	9.35 Bn	668.28 Mn	-35.57%
8	Insmed	27.47 Bn	26.31 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.32 Bn	26.49 Bn	-	19.75%
10	Tenax Therapeutics	79.15 Mn	79.15 Mn	-	-

Download Data